Abstracts Archive - Page 1050 of 2607 - ACR Meeting Abstracts

Abstract Number: 1648 • 2019 ACR/ARP Annual Meeting
Systemic Sclerosis Auto-antibody Profiles Predict Interstitial Lung Disease Onset but Not Progression
Boyang Zheng¹, Mianbo Wang ², Marvin Fritzler ³, May Choi ³, Murray Baron ⁴ and Marie Hudson ⁵, ¹Jewish General Hospital, McGill University, Montreal, QC, Canada, ²Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada, ³Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁴Jewish General Hospital, McGill University, Montreal, Canada, ⁵Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada
Background/Purpose: Interstitial lung disease (ILD) is frequent manifestation and a leading cause of mortality in systemic sclerosis (SSc). Some SSc-related autoantibodies (aAbs), especially anti-topoisomerase I…
Abstract Number: 1649 • 2019 ACR/ARP Annual Meeting
Mycophenolate Mofetil and Cyclophosphamide Improve Health-Related Quality of Life in Patients with Systemic Sclerosis Who Participated in SLS II
Elizabeth Volkmann¹, Donald Tashkin ², Michael Roth ³, Holly LeClair ², Philip Clements ², Daniel Furst ⁴, Robert Elashoff ² and Dinesh Khanna ⁵, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ²University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ³University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴University of California, Los Angeles, CA, ⁵Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of morbidity and mortality in systemic sclerosis (SSc). The majority of studies investigating novel therapies for…
Abstract Number: 1650 • 2019 ACR/ARP Annual Meeting
Baseline Skin Score, Older Age and CD34-selection Influence the Outcome of Autologous Stem Cell Transplantation for Systemic Sclerosis – Results of a Prospective Non-interventional Study from the European Society for Blood & Marrow Transplantation (EBMT)
Joerg Henes¹, Maria Carolina Oliveira ², Myriam Labopin ³, Manuela Badoglio ⁴, Hans Ulrich Scherer ⁵, Nicoletta Del Papa ⁶, Thomas Daikeler ⁷, Marc Schmalzing ⁸, Roland Schroers ⁹, Thierry Martin ¹⁰, Grégory Pugnet ¹¹, Belinda Simoes ¹², David Michonneau ¹³, Erik Marijt ¹⁴, Bruno Lioure ¹⁵, Jacques Olivier Bay ¹⁶, John Snowden ¹⁷, Montserrat Rovira ¹⁸, Anne Huynh ¹⁹, Francesco Onida ²⁰, Lothar Kanz ¹, Zora Marjanovic ²¹ and Dominique Farge ²², ¹University Hospital Tuebingen, Department of Internal Medicine II (Oncology, Haematology, Immunology and Rheumatology), Tuebingen, Germany, ²Ribeirão Preto Medical School, University of São Paulo, Sao Paulo, Brazil, ³EBMT Paris Study Office, Saint Antoine Hospital, Université Pierre et Marie Curie, Paris, France, ⁴EBMT Paris Study Office, Hôpital St Antoine, Paris, France, ⁵Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands, ⁶Scleroderma Clinic, Osp. G. Pini, Department of Rheumatology, Milan, Italy, ⁷University and University Hospital of Basel, Department of Rheumatology, Basel, Switzerland, ⁸Universitätsklinikum Würzburg, Department of Rheumatology/ Clinical Immunology, Wuerzburg, Germany, ⁹University Hospital of Bochum, Med. Klinik, Bochum, Germany, ¹⁰Hôpitaux Universitaires de Strasbourg Service de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes Systémiques Rares Est-Sud-Ouest (RESO), Strasbourg, France, ¹¹CHU de Toulouse, Hôpital Purpan, Service de Médecine Interne, Toulouse, France, ¹²Ribeirão Preto Medical School, University of São Paulo, Division of Hematology, Sao Paulo, Brazil, ¹³Hôpital Saint Louis & Université Paris 7, Denis Diderot, Department of Hematology, Paris, France, ¹⁴Leiden University Medical Center, Department of Hematology, Leiden, Netherlands, ¹⁵Strasbourg University Hospital, Department of Hematology, Strasbourg, France, ¹⁶CHU de Clermont Ferrand, Department of Hematology, Clermont Ferrand, France, ¹⁷Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom, ¹⁸Hospital Clínic of Barcelona, Department of Haematology, Barcelona, Spain, ¹⁹UCT Oncopole, Department of Haematology, Toulouse, France, ²⁰Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy, ²¹Saint Antoine Hospital, Department of Haematology, Paris, France, ²²Hôpital Saint-Louis, AP-HP Assistance Publique des Hôpitaux de Paris, Centre de Référence des Maladies Auto-Immunes Systémiques Rares d’Ile-de-France, Filière ‘FAI2R’, Unité de Médecine Interne: Maladies Auto-immunes et Pathologie Vasculaire (UF 04), Université de Paris, EA 3518, Paris, France; Department of Medicine, McGill University, Montreal, QC, Canada, Paris, France
Background/Purpose: TThree randomized controlled trials in systemic sclerosis (SSc) demonstrated that autologous hematopoietic stem cell transplantation (aHSCT) is superior to standard cyclophosphamide therapy. This EBMT…
Abstract Number: 1651 • 2019 ACR/ARP Annual Meeting
Multicenter Double-Blind, Proof-of-Concept, Randomized Placebo-Controlled Trial of Riociguat in Systemic Sclerosis-associated Digital Ulcers
Vivek Nagaraja¹, Cathie Spino ¹, Pei-Suen Tsou ¹, Robyn Domsic ², Robert Lafyatis ², Tracy Frech ³, Jessica Gordon ⁴, Virginia Steen ⁵ and Dinesh Khanna ⁶, ¹University of Michigan, Ann Arbor, MI, ²University of Pittsburgh, Pittsburgh, PA, ³Division of Rheumatology, University of Utah and Salt Lake VAMC, Salt Lake City, UT, ⁴Hospital for Special Surgery, New York, NY, ⁵Georgetown University, Washington, D.C., USA, Georgetown, ⁶Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor
Background/Purpose: The soluble guanylate cyclase stimulator riociguat (RIO) is a vasodilator with efficacy in patients with pulmonary arterial hypertension associated with connective tissue disease. Our…
Abstract Number: 1652 • 2019 ACR/ARP Annual Meeting
Anticentromere Antibody Levels and Isotypes Associate with Disease Severity in Systemic Sclerosis
Nina van Leeuwen¹, Jaap Bakker ¹, Annette Grummels ¹, Corrie Wortel ¹, Suzana Jordan ², Oliver Distler ³, Håvard Fretheim ⁴, Anna Maria Hoffmann-Vold ⁵, Hans Ulrich Scherer ⁶, René Toes ¹, Thomas Huizinga ¹ and Jeska de Vries-Bouwstra ¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, Zurich, Switzerland, ³Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ⁴University Hospital Oslo, Oslo, Norway, ⁵Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁶Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands
Background/Purpose: Although some studies suggest a possible association between clinical characteristics and isotypes of anticentromere antibodies (ACA) in patients with systemic sclerosis (SSc), characteristics of…
Abstract Number: 1653 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Romilkimab in Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Randomized, Double-Blind, Placebo-Controlled, 24-week, Proof of Concept Study
Yannick Allanore¹, Christopher Denton ², Dinesh Khanna ³, Christina Soubrane ⁴, Corinne Esperet ⁴, Frederic Marrache ⁴, Raphael Bejuit ⁴, Amel Lahmar ⁵ and Peter Wung ⁵, ¹Dept. of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, ²University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom, ³Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ⁴Sanofi, Chilly Mazarin, France, ⁵Sanofi, Bridgewater, NJ
Background/Purpose: Systemic sclerosis (SSc) is a progressive, multi-organ disease with limited treatment options. Interleukin-4 (IL-4) and IL-13 have been implicated in the general fibrotic pathway…
Abstract Number: 1654 • 2019 ACR/ARP Annual Meeting
Esophageal Dilation and Other Clinical Factors Associated with Pulmonary Function Decline in Patients with Systemic Sclerosis
Kimberly Showalter¹, Aileen Hoffmann ², Carrie Richardson ³, Kimberly Koloms ², Gerald Rouleau ², David Aaby ², Julia (Jungwha) Lee ⁴, Jane Dematte ², Rishi Agrawal ², Xiaoping Wu ⁵, Rowland Chang ⁴ and Monique Hinchcliff ⁶, ¹Hospital for Special Surgery, New York, NY, ²Northwestern University Feinberg School of Medicine, Chicago, ³Rush University, Chicago, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵New York Presbyterian/Weill Cornell, New York, ⁶Yale University, Section of Rheumatology, Allergy and Immunology, New Haven, CT
Background/Purpose: Prior work has shown that Scl-70 positive autoantibody status and baseline c-reactive protein (CRP) are associated with more rapid pulmonary function decline in patients…
Abstract Number: 1655 • 2019 ACR/ARP Annual Meeting
Histologic Features Correlate with the Modified Rodnan Skin Score, Serum Inflammatory Markers, and Patient Reported Outcomes in Patients with Early, Diffuse Cutaneous Systemic Sclerosis
Kimberly Showalter¹, Cynthia Magro ², Dana Orange ³, Yaxia Zhang ⁴, Phaedra Agius ⁵, Jackie Finik ⁶, Robert Spiera ¹ and Jessica Gordon ¹, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, ³Rockefeller University, New York, ⁴Hospital for Special Surgery, New York, ⁵New York Genome Center, New York City, ⁶Hospital for Special Surgery, New York, NY, New York, NY
Background/Purpose: The association between systemic sclerosis (SSc) skin histology and clinical findings is not fully characterized. In two SSc trials, we developed a scoring system…
Abstract Number: 1656 • 2019 ACR/ARP Annual Meeting
Health-Related Quality of Life in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Impact of Lung Function on Patient-Reported Outcomes in a Randomized Phase III Trial
Michael Kreuter ¹, Anna Maria Hoffmann-Vold ², Marco Matucci-Cerinic ³, Lesley Saketkoo ⁴, Kristin Highland⁵, Hilary Wilson ⁶, Margarida Alves ⁷, Nils Schoof ⁶ and Toby Maher ⁸, ¹Center for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik, University of Heidelberg, Member of the German Center for Lung Research, Germany, Germany, Germany, ²Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ³University of Florence, Department of Medicine, Florence, Italy, Florence, Italy, ⁴New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans; Tulane University School of Medicine, University Medical Center – Comprehensive Pulmonary Hypertension Center, USA, New Orleans, ⁵Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, ⁶Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, ⁷Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁸National Heart and Lung Institute, Imperial College London, UK and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, London, United Kingdom
Background/Purpose: SSc-ILD is a major cause of morbidity and mortality in patients with systemic sclerosis. A subset of patients with SSc-ILD show a decline in…
Abstract Number: 1657 • 2019 ACR/ARP Annual Meeting
Sarcopenia in Systemic Sclerosis
Iván Dario Remolina Rincón¹, Maria Alak ², Graciela Alsina ³, Pedro Quevedo ², Mariano Rivero ⁴ and Damian Duartes ⁵, ¹Hospital Británico, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ²Hospital Britanico de Buenos Aires, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ³Consultorios Pampa, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁴Hospital Británico, Buenos Aires, Buenos Aires, Argentina, ⁵Hospital Británico, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina
Background/Purpose: Gastrointestinal tract involvement in systemic sclerosis (SSc) occurs in almost all patients varying in severity and affecting motility, digestion, absorption and excretion. These abnormalities…
Abstract Number: 1658 • 2019 ACR/ARP Annual Meeting
Impact of Visceral Involvement in the Characterization and Prognosis of Patients Without Skin Involvement Classified as Systemic Sclerosis (SSc) According to 2013 ACR/EULAR Criteria in a Large Single Cohort
Ana Ribeiro¹, Ana Paula Luppino-Assad ², Henrique Silva ³, Leandro Prado ³, Danieli Andrade ⁴ and Percival Degrava Sampaio-Barros ⁵, ¹HOSPITAL DAS CLINICAS DA FACULDADE DE MEDICINA DE SAO PAULO, Sao Paulo, Brazil, ²Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil., Sao Paulo, Brazil, ³HOSPITAL DAS CLINICAS DA FACULDADE DE MEDICINA DA UNIVERSIDADE DE SAO PAULO, Sao Paulo, Brazil, ⁴Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, Sao Paulo, Brazil, ⁵Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, Brazil, Sao Paulo, Brazil
Background/Purpose: The 2013 ACR/EULAR classification criteria for systemic sclerosis (SSc) allowed the inclusion of a subset of patients without skin involvement, not considered by the…
Abstract Number: 1659 • 2019 ACR/ARP Annual Meeting
Linaclotide for the Treatment of Gastrointestinal Symptoms in Systemic Sclerosis
Eric Dein¹, John Clarke ², Frederick Wigley ³ and Zsuzsanna McMahan* ³, ¹Johns Hopkins, Baltimore, MD, ²Stanford, Pao Alto, ³Johns Hopkins University, Division of Rheumatology, Baltimore
Background/Purpose: Gastrointestinal (GI) involvement is the most common internal organ affected in systemic sclerosis (SSc). Constipation is a common GI complication in SSc that affects…
Abstract Number: 1660 • 2019 ACR/ARP Annual Meeting
Serial Sublingual Videomicroscopy in Systemic Sclerosis Clinic: Are the Microcirculation Measurements Correlated with Gastrointestinal Symptoms?
Tracy Frech¹, Guo Wei ² and Maureen Murtaugh ³, ¹Division of Rheumatology, University of Utah and Salt Lake VAMC, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³University of Utah and Salt Lake VAMC, Salt Lake City
Background/Purpose: Intravital microscopy of the sublingual microcirculation provides estimates of perfused barrier region (PBR) and red blood cell fraction (RBCfract), which quantifies vasculopathy and, similar…
Abstract Number: 1661 • 2019 ACR/ARP Annual Meeting
Circulating Cell Free DNA Released from Eosinophils Is a Practical Biomarker in Patients with Eosinophilic Granulomatosis with Polyangiitis
Teppei Hashimoto¹, Yuichi Yokoyama ², Tetsuya Furukawa ³, Takahiro Yoshikawa ³, Naoto Azuma ², Kohsuke Yoshida ⁴, Akira Hashiramoto ⁴ and Kiyoshi Matsui ³, ¹Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Kobe, Hyogo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan, ³Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan, ⁴Kobe University Graduate School of Health Sciences, Kobe, Hyogo, Japan
Background/Purpose: Fragmented cell-free DNA (cfDNA) is released into blood circulation as results of damage or death of peripheral blood cells as well as organ tissues,…
Abstract Number: 1662 • 2019 ACR/ARP Annual Meeting
Does PR3-ANCA+ Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss)Really Exist?
Matthias Papo¹, Renato A. Sinico ², Vítor Teixeira ³, Maria-Letizia Urban ⁴, Juliane Mahrhold ⁵, Francesco Locatelli ⁶, Giulia Cassone ⁷, Franco Schiavon ⁸, Benjamin Seeliger ⁹, Thomas Neumann ¹⁰, Claus Kroegel ¹¹, Matthieu Groh ¹², Chiara Marvisi ¹³, Maxime Samson ¹⁴, Thomas Barba ¹⁵, David Jayne ¹⁶, Bernhard Hellmich ⁵, Sara Monti ¹⁷, Carlomaurizio Montecucco ⁶, Carlo Salvarani ¹⁸, Jean-Emmanuel Kahn ¹², Cécile-Audrey Durel ¹⁵, Loic Guillevin ¹⁹, Giacomo Emmi ⁴, Augusto Vaglio ²⁰ and Benjamin Terrier ¹⁹, ¹Department of Internal Medicine, Hôpital Cochin, Université Paris Descartes, Sorbonne Paris Cité, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, Paris, France, Paris, France, ²Department of Medicine and Surgery, Università degli Studi di Milano - Bicocca , Italy, Milan, Italy, ³Rheumatology and Bone Diseases Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte; Lisbon, Portugal., Lisbon, Portugal, ⁴Department of Experimental and Clinical Medicine, University of Firenze, Florence, Italy, Florence, Italy, ⁵Department of Internal Medicine, Rheumatology and Immunology, Vasculitis-Center Tübingen-Kirchheim, Medius Klinik Kirchheim, University of Tübingen, Kirchheim-Teck, Germany, Kirchheim, Germany, ⁶Department of Rheumatology, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy, Pavia, Italy, ⁷Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy. Rheumatology Unit, IRCCS Arcispedale Santa Maria Nuova, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy, Modena and Reggio Emilia, Italy, ⁸Operative Unit of Rheumatology, Department of Medicine DIMED, University of Padova, Padova, Italy, Padova, Italy, ⁹Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany, Hannover, Germany, ¹⁰Division of Rheumatology and Immunolog, Kantonsspital St. Gallen, St. Gallen, Sankt Gallen, Switzerland, ¹¹Department of Pneumology and Allergology, Clinic of Internal Medicine I, Jena University Hospital, Jena, Germany, Jena, Germany, ¹²Service de Médecine Interne, Centre de Référence des Syndromes Hyperéosinophiliques-CEREO, Hôpital Foch, Université Versailles–Saint-Quentin-en-Yvelines, Suresnes, France, Suresnes, France, ¹³Nephrology Unit, Parma University Hospital, Parma, Italy, Parma, Italy, ¹⁴CHU Dijon, Dijon, France, ¹⁵Department of Internal Medicine, Hôpital Edouard Herriot, Lyon, France, Lyon, France, ¹⁶Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Cambridge, United Kingdom, ¹⁷University of Pavia, Pavia, Italy, ¹⁸Division of Rheumatology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, ¹⁹National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France, ²⁰Nephrology Unit, Parma University Hospital, Parma, Italy, Nephrology Unit, Parma University Hospital, Parma, Italy, Italy
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) (Churg–Strauss) is a small-vessel necrotizing vasculitis characterized by blood and tissue eosinophilia and asthma. Only a third of EGPA…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].